卵巢癌的过继免疫治疗bs- mab靶向淋巴细胞:一项多中心研究

International journal of cancer. Supplement = Journal international du cancer. Supplement Pub Date : 1992-01-01

R L Bolhuis, C H Lamers, S H Goey, A M Eggermont, J B Trimbos, G Stoter, A Lanzavecchia, E di Re, S Miotti, F Raspagliesi

{"title":"卵巢癌的过继免疫治疗bs- mab靶向淋巴细胞:一项多中心研究","authors":"R L Bolhuis, C H Lamers, S H Goey, A M Eggermont, J B Trimbos, G Stoter, A Lanzavecchia, E di Re, S Miotti, F Raspagliesi","doi":"","DOIUrl":null,"url":null,"abstract":"A bispecific monoclonal antibody (bs-MAb) (OC/TR) was produced in large quantities for the intraperitoneal (i.p.) treatment of ovarian cancer. The bs-MAb recognizes the folate-binding protein on ovarian cancer cells on the one hand and the CD3 activation site on T lymphocytes on the other. T lymphocytes were expanded ex vivo, targeted with OC/TR in vitro and administered to the i.p. cavity in the presence of soluble OC/TR. All patients developed human anti-mouse-antibodies (HAMA). In the Dutch study, 2 complete remissions (CR) were seen, 2 partial regressions (PR), I stable disease (SD) and I progressive disease (PD). In the Italian study 3 CR, I PR, I SD and 2 PD were seen.","PeriodicalId":77178,"journal":{"name":"International journal of cancer. Supplement = Journal international du cancer. Supplement","volume":"7 ","pages":"78-81"},"PeriodicalIF":0.0000,"publicationDate":"1992-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Adoptive immunotherapy of ovarian carcinoma with bs-MAb-targeted lymphocytes: a multicenter study.\",\"authors\":\"R L Bolhuis, C H Lamers, S H Goey, A M Eggermont, J B Trimbos, G Stoter, A Lanzavecchia, E di Re, S Miotti, F Raspagliesi\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"A bispecific monoclonal antibody (bs-MAb) (OC/TR) was produced in large quantities for the intraperitoneal (i.p.) treatment of ovarian cancer. The bs-MAb recognizes the folate-binding protein on ovarian cancer cells on the one hand and the CD3 activation site on T lymphocytes on the other. T lymphocytes were expanded ex vivo, targeted with OC/TR in vitro and administered to the i.p. cavity in the presence of soluble OC/TR. All patients developed human anti-mouse-antibodies (HAMA). In the Dutch study, 2 complete remissions (CR) were seen, 2 partial regressions (PR), I stable disease (SD) and I progressive disease (PD). In the Italian study 3 CR, I PR, I SD and 2 PD were seen.\",\"PeriodicalId\":77178,\"journal\":{\"name\":\"International journal of cancer. Supplement = Journal international du cancer. Supplement\",\"volume\":\"7 \",\"pages\":\"78-81\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1992-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International journal of cancer. Supplement = Journal international du cancer. Supplement\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of cancer. Supplement = Journal international du cancer. Supplement","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

大量生产了一种双特异性单克隆抗体(bs-MAb) (OC/TR)，用于腹腔(i.p)治疗卵巢癌。bs-MAb一方面识别卵巢癌细胞上的叶酸结合蛋白，另一方面识别T淋巴细胞上的CD3激活位点。T淋巴细胞在体外扩增，OC/TR在体外靶向，并在可溶性OC/TR存在下给药于上颌腔。所有患者均产生人抗小鼠抗体(HAMA)。在荷兰的研究中，2例完全缓解(CR)， 2例部分消退(PR)， 1例病情稳定(SD)， 1例病情进展(PD)。在意大利的研究中，有3例CR, 1例PR, 1例SD和2例PD。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

本刊更多论文

Adoptive immunotherapy of ovarian carcinoma with bs-MAb-targeted lymphocytes: a multicenter study.

A bispecific monoclonal antibody (bs-MAb) (OC/TR) was produced in large quantities for the intraperitoneal (i.p.) treatment of ovarian cancer. The bs-MAb recognizes the folate-binding protein on ovarian cancer cells on the one hand and the CD3 activation site on T lymphocytes on the other. T lymphocytes were expanded ex vivo, targeted with OC/TR in vitro and administered to the i.p. cavity in the presence of soluble OC/TR. All patients developed human anti-mouse-antibodies (HAMA). In the Dutch study, 2 complete remissions (CR) were seen, 2 partial regressions (PR), I stable disease (SD) and I progressive disease (PD). In the Italian study 3 CR, I PR, I SD and 2 PD were seen.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

International journal of cancer. Supplement = Journal international du cancer. Supplement

自引率

0.00%

发文量